Lamotrigine (LTG) is a frequently prescribed antiepileptic and mood-stabilizing drug, which is associated with cutaneous adverse drug reactions (cADRs). The clinical spectrum of these reactions is wide and ranges from the common mild maculopapular exanthema (MPE) to drug reactions with eosinophilia and systemic symptoms (DRESS) and the rare and life-threatening blistering reactions, such as Stevens Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) [1,2]. Although MPE is not a severe adverse reaction by itself, it is still a major cause of drug discontinuation [3,4].
25
ABR
ABR
0